What question did this study set out to answer?

This trial evaluates the effectiveness and safety of autologous micrografts containing fibroblasts for rejuvenating facial skin.

June 3, 2026JPRAS Open0 citationsOpen Access

Autologous Fibroblast Therapy for Facial Rejuvenation: A Randomized Open-Label Controlled Study

PGPietro GentileUniversity of Rome Tor Vergata

Key Points

This trial evaluates the effectiveness and safety of autologous micrografts containing fibroblasts for rejuvenating facial skin.
Randomized, open-label, controlled study with 40 participants divided into treatment and control groups.
Participants received autologous micrografts or hyaluronic acid at baseline, one month, and three months, with follow-up assessments at six and twelve months.
Clinical outcomes were measured using Wrinkle Severity Rating Scale and objective skin elasticity metrics.
The treatment group showed significantly greater improvements in wrinkle depth and skin elasticity at 12 months (**p < 0.01**).
Physicians rated improvements from 9 to 4 in the treatment group (**p = 0.049**), compared to control ratings.
Patient self-assessments improved from 9 to 5 in the treatment group (**p = 0.039**), with higher overall satisfaction.

Abstract

AbstractBackground The aging process of the face is characterized by dermal thinning, loss of elasticity, and wrinkle formation. Injection of autologous micrografts containing fibroblasts (Am-FBs) has emerged as a promising regenerative technique. Objectives This trial aims to assess the efficacy and safety of Am-FBs for facial rejuvenation. Methods A randomized, open-label, controlled study was conducted. Forty patients presenting with mild to moderate dermal thinning, reduced elasticity, and wrinkles were divided into two groups: a study group (SG; n = 20) that received Am-FBs treatment and a control group (CG; n = 20) treated with a hyaluronic acid (HA)–based skin booster. Both groups received treatment at baseline (T0), at one month (T1), and at three months (T2). Clinical outcomes were evaluated at T1, T2, T3 (6 months), and T4 (12 months) through patient and physician evaluations, the Wrinkle Severity Rating Scale (WSRS), and objective skin elasticity metrics. In vitro evaluation of the Am-FBs and immunophenotypic characterization of the nucleated cell population contained in the Am-FBs suspension was performed. Results At T4, the SG showed significantly greater improvements in wrinkle depth, skin elasticity, and WSRS score than the CG (p p = 0.049), whereas patient self-assessments ranged from 9 to 5 (p = 0.039). Patient satisfaction was higher in the SG. The in vitro analysis documented 2.780.750 nucleated cells/ml in Am-FBs with a viability of 89.61% and immunophenotype: CD34%0.2, CD45%0.2, CD44%98.7, CD200%80.0, Cytokeratin 15%99.4. Conclusions Am-FBs significantly improve signs of facial aging and present a safe option for skin rejuvenation.

Demander à l'IA

Bookmark

View Full Paper